CD8A and COVID-19: Two injections of 1–50 μg of BNT162b1 induced intense antibody production, with RBD-binding IgG titers and CD4+ and CD8+ T-cell responses far exceeding those observed in the sera of individuals who recovered from COVID-19 [20].